Some former users allege that the term discontinuation syndrome, which was the initial and or continued label for effexor withdrawal, may have been a mistake when referring to the drug.
A second longer-term study has demonstrated the efficacy of effexor in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then randomly assigned to placebo or effexor for periods of up to 52 weeks on the same dose 100 to 200 mg day, on a b.